文献速递胃肠动力与功能性疾病

薄荷油治疗肠易激综合征随机双盲试验的疗效与安全性

Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.
PubMed 文献 · Gastroenterology · 2019-08-27

在荷兰4家医院纳入190例罗马IV标准肠易激综合征患者,随机接受182 mg小肠释放薄荷油、回结肠释放薄荷油或安慰剂治疗8周。按FDA/EMA终点,薄荷油组腹痛应答率和整体症状缓解率与安慰剂无显著差异,但小肠释放薄荷油在腹痛、不适和IBS严重度等次要终点上优于安慰剂,不良事件虽轻但更常见。

核心结论

  • 小肠释放和回结肠释放薄荷油治疗8周均未在FDA/EMA推荐的腹痛应答或整体症状缓解终点上产生统计学显著改善。
  • 小肠释放薄荷油显著改善腹痛、不适和IBS严重度等次要终点。
  • 研究结果不支持进一步开发回结肠释放薄荷油用于治疗IBS。

研究设计与样本

  • 双盲随机对照试验,2016年8月至2018年3月在荷兰4家医院纳入190例罗马IV标准IBS患者。
  • 189例纳入意向治疗分析(平均年龄34.0岁,女性77.8%,57.7%来自初级保健),178例完成研究。
  • 患者随机接受182 mg小肠释放薄荷油、182 mg回结肠释放薄荷油或安慰剂治疗8周。
  • 主要终点为FDA定义的腹痛应答:每周最严重日腹痛平均值较基线下降至少30%且持续至少4周。
  • 共同主要终点为EMA定义的IBS整体症状缓解。

关键数值与推荐

  • 腹痛应答定义:每周最严重日腹痛平均值较基线下降至少30%,且在至少4周内达到。
  • 整体症状缓解采用EMA定义。
  • 薄荷油剂量:182 mg小肠释放或回结肠释放,疗程8周。

临床怎么用

  • 对于IBS患者,小肠释放薄荷油182 mg治疗8周可能改善腹痛、不适和IBS严重度等次要结局。
  • 按FDA/EMA主要终点,薄荷油未显示显著优于安慰剂的腹痛应答或整体症状缓解。
  • 回结肠释放薄荷油的研究结果不支持进一步开发用于IBS治疗。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Peppermint oil is frequently used to treat irritable bowel syndrome (IBS), despite a lack of evidence for efficacy from high-quality controlled trials. We studied the efficacy and safety of small-intestinal-release peppermint oil in patients with IBS and explored the effects of targeted ileocolonic-release peppermint oil. METHODS: We performed a double-blind trial of 190 patients with IBS (according to Rome IV criteria) at 4 hospitals in The Netherlands from August 2016 through March 2018; 189 patients were included in the intent-to-treat analysis (mean age, 34.0 years; 77.8% female; 57.7% in primary care), and 178 completed the study. Patients were randomly assigned to groups given 182 mg small-intestinal-release peppermint oil, 182 mg ileocolonic-release peppermint oil, or placebo for 8 weeks. The primary endpoint was abdominal pain response, as defined by the US Food and Drug Administration: at least a 30% decrease in the weekly average of worst daily abdominal pain compared with baseline in at least 4 weeks. The co-primary endpoint was overall relief of IBS symptoms, as defined by the European Medicines Agency. Secondary endpoints included abdominal pain, discomfort, symptom severity, and adverse events. RESULTS: Abdominal pain response did not differ significantly between the peppermint oil and placebo groups: 29 of 62 patients in the small-intestinal-release peppermint oil group had a response (46.8%, P = .170 vs placebo), 26 of 63 patients in the ileocolonic-release peppermint oil group had a response (41.3%, P = .385 vs placebo), and 22 of 64 patients in the placebo group had a response (34.4%). We did not find differences among the groups in overall relief (9.7%, P = .317 and 1.6%, P = .351 vs 4.7% for placebo). The small intestinal peppermint oil did, however, produce greater improvements than placebo in secondary outcomes of abdominal pain (P = .016), discomfort (P = .020), and IBS severity (P = .020). Adverse events, although mild, were more common in both peppermint oil groups (P < .005). CONCLUSIONS: In a randomized trial of patients with IBS, we found that neither small-intestinal-release nor ileocolonic-release peppermint oil (8 weeks) produced statistically significant reductions in abdominal pain response or overall symptom relief, when using US Food and Drug Administration/European Medicines Agency recommended endpoints. The small-intestinal-release peppermint oil did, however, significantly reduce abdominal pain, discomfort, and IBS severity. These findings do not support further development of ileocolonic-release peppermint oil for treatment of IBS. Clinicaltrials.gov, Number: NCT02716285.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Weerts ZZRM, Masclee AAM, Witteman BJM, et al. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome. Gastroenterology. 2019. PMID: 31470006. doi:10.1053/j.gastro.2019.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。